EISAI CO

Emerging Alzheimer’s therapies like Eli Lilly’s Kisunla and Eisai/Biogen’s Leqembi face regulatory and access challenges, highlighting the need for balancing clinical rigor with patient convenience. Decentralised clinical trials (DCTs) in Alzheimer’s have declined, with only 7.09% of trials conducted as DCTs by 2023. Eli Lilly leads in DCT use, with Kisunla frequently investigated. Ensuring patient and caregiver convenience while collecting robust data is crucial, especially for long-term studies. Digital health technologies like telemedicine and wearables offer potential to improve data quality and patient recruitment, though challenges remain in technology integration and patient comfort.

Alzheimer’s disease therapeutics market includes symptomatic treatments (cholinesterase inhibitors, NMDA receptor antagonists) and disease-modifying therapies (anti-amyloid monoclonal antibodies). Market growth driven by aging population, diagnostic advancements, and R&D investments. Market expected to grow from USD 5.5 billion in 2023 to USD 30.8 billion by 2033 at 18.8% CAGR. Major companies include Biogen, Merck, GSK, Novartis, Johnson & Johnson, Bristol Myers Squibb, Sanofi, Pfizer, Teva Pharmaceutical, and AbbVie, each with strategic initiatives and collaborations in Alzheimer’s research.

The EU approves Leqembi, a drug to delay Alzheimer's onset, for patients not in advanced stages, despite initial rejection due to risk of brain bleeding. The UK also approved it under the name lecanemab, with a controlled availability program to manage risks.

Eisai and Biogen received a positive CHMP opinion recommending approval of lecanemab, an Aß monoclonal antibody for early Alzheimer’s disease in ApoE e4 non-carriers or heterozygotes. Lecanemab selectively binds to Aß aggregates, reducing protofibrils and plaques. The CHMP's positive opinion was based on phase 3 Clarity AD trial data, showing significant reduction in clinical decline. Lecanemab has been approved in several countries and is under review in others.

A groundbreaking Alzheimer's drug, Leqembi, has been approved for use in the EU, targeting amyloid plaques. Initially blocked in July, the European Medicines Agency (EMA) approved it in August, recommending it for patients not in advanced stages. Developed by Eisai and Biogen, it's also approved in the US, Japan, and China. The drug is available in the UK under a different name, with potential side effects including ARIA. The EMA's approval is restricted to patients with lower risk of brain hemorrhage and fewer copies of the ApoE4 gene.

EMA approves Leqembi, first treatment for slowing Alzheimer's cognitive decline, reversing earlier rejection due to side effect concerns. Targeting early signs, it shows reduced cognitive decline in trials, but is limited to mild cases and those without ApoE4 gene risk. Developed by Eisai and Biogen, it has been approved globally, offering hope but not a cure, with potential to transform neurodegenerative disease treatment landscapes.

The article discusses the implementation of a Server-Side Rendering (SSR) service entry, identified by the file '/bundles/v1/views/latest/SSR-service-entry.c49d8207ea51fe4b43e4.js', within a web page structure.

The EU approves Leqembi, a life-changing Alzheimer's drug, for patients not in advanced stages, after initial rejection due to risks like brain bleeding. The treatment, developed by Eisai and Biogen, is also approved in the UK, US, Japan, and China. It targets amyloid plaques and is available under different names in various countries, with a controlled release to manage risks.

The article discusses the use of SSR (Server-Side Rendering) in web development, focusing on its implementation and benefits.

Subscribe to BioWorld™ news services.